Finland· FI-REL-REL64604

Rapiscan

A regadenoson product containing regadenoson, registered in Finland by Abacus Medicine A/S. The same ATC class is registered in 13 of our 19 countries.

ATC C01EB21

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedRapiscanATCC01EB21REGISTER NO.FI-REL-REL64604PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Regadenoson is registered in 13 of 19 countries.

Countries holding a registration under ATC C01EB21 (regadenoson), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 9 of them publish a price we can compare per daily dose

Regadenoson · ATC C01EB21

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Regadenoson
Manufacturer
Abacus Medicine A/S
Country
Finland (FI)
ATC code
C01EB21
ATC class
Regadenoson
Defined daily dose
0.4 mg, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

6 interactions on record for regadenoson.

Graded by severity as the source publishes them — 6 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Regadenoson · interactions on record

6 records

  • 6 moderate

Most severe, free to view

  • DipyridamoleB01AC07moderate
  • DipyridamolC01DX29moderate
  • TheophyllinC01EB28moderate
  • CaffeineN06BC01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Regadenoson in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All regadenoson products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Rapiscan
  • Iceland · Rapiscan
  • Liechtenstein · Rapiscan
  • Norway · Rapiscan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8d7f7e00-9e98-4b86-b325-20142cd0cb36
GET /v1/drugs/8d7f7e00-9e98-4b86-b325-20142cd0cb36?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.4",
  "form": "injektioneste, liuos",
  "route": "Laskimoon",
  "ddd_unit": "mg",
  "strength": "400 mikrog",
  "atc_label": "regadenosoni",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/10/643/001",
  "fimea_rel_id": "REL64604",
  "authorised_at": "2025-08-22"
}

See everything about regadenoson.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.